Maintenance Therapy Combo Bolsters Survival in Extensive-Stage SCLC
Findings suggest that adding lurbinectedin to atezolizumab for first-line maintenance therapy benefits patients with extensive-stage small cell lung cancer.
Jun 11, 2025
MEETING BRIEF
ASCO 2025 – SCLC
The latest news from ASCO 2025 focusing on SCLC including abstracts, features, and helpful conference information.
Immune Biomarkers Differentiate Early Progression from Long-Term Survival in Limited-Stage Small-Cell Lung Cancer
Immune Biomarkers Differentiate Early Progression from Long-Term Survival in Limited-Stage Small-Cell Lung Cancer
New findings from the ADRIATIC trial revealed that distinct immune biomarkers may help identify patients with limited-stage small-cell lung cancer who are more likely to experience long-term progression-free survival after chemoradiotherapy.
Outpatient Tarlatamab Administration Feasible in Relapsed SCLC With Close Monitoring
Outpatient Tarlatamab Administration Feasible in Relapsed SCLC With Close Monitoring
Outpatient tarlatamab administration for relapsed small cell lung cancer was feasible and safe with proper monitoring, according to findings presented at ASCO.
Combined Immunotherapy & Chemotherapy Improves Survival in Extensive-Stage SCLC
Combined Immunotherapy & Chemotherapy Improves Survival in Extensive-Stage SCLC
Real-world data show first-line chemo-immunotherapy improves survival and response rates over chemo alone in extensive-stage SCLC, supporting its broader use.
Second-Line & Later Therapies Show Promising Outcomes in Small Cell Lung Cancer
Second-Line & Later Therapies Show Promising Outcomes in Small Cell Lung Cancer
Lurbinectedin showed clinical benefit across therapy lines in SCLC, with best responses seen in later lines and with prior immunotherapy exposure.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
